SB-366791
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522592

CAS#: 472981-92-3

Description: SB-366791 is a potent and selective TRPV1 antagonist. SB-366791 inhibits glutamatergic synaptic transmission in rat spinal dorsal horn following peripheral inflammation. SB-366791 decreased capsaicin-induced Ca2+ influx in cultured trigeminal ganglion cells in a concentration-dependent manner (0.5-10 microM) with an IC50 of 651.9 nM. SB366791 is a more selective and in vivo also a more potent TRPV1 receptor antagonist than capsazepine in the rat therefore, it may promote the assessment of the therapeutic utility of TRPV1 channel blockers.


Chemical Structure

img
SB-366791
CAS# 472981-92-3

Theoretical Analysis

MedKoo Cat#: 522592
Name: SB-366791
CAS#: 472981-92-3
Chemical Formula: C16H14ClNO2
Exact Mass: 287.07
Molecular Weight: 287.740
Elemental Analysis: C, 66.79; H, 4.90; Cl, 12.32; N, 4.87; O, 11.12

Price and Availability

Size Price Availability Quantity
50mg USD 250
100mg USD 450 2 Weeks
200mg USD 750 2 Weeks
500mg USD 1650 2 Weeks
1g USD 2950 2 Weeks
2g USD 5250 2 Weeks
Bulk inquiry

Synonym: SB-366791; SB 366791; SB366791.

IUPAC/Chemical Name: 3-(4-chlorophenyl)-N-(3-methoxyphenyl)-2-propenamide

InChi Key: RYAMDQKWNKKFHD-JXMROGBWSA-N

InChi Code: InChI=1S/C16H14ClNO2/c1-20-15-4-2-3-14(11-15)18-16(19)10-7-12-5-8-13(17)9-6-12/h2-11H,1H3,(H,18,19)/b10-7+

SMILES Code: O=C(NC1=CC=CC(OC)=C1)/C=C/C2=CC=C(Cl)C=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Biological target: SB-366791 is a VR1/TRPV1 antagonist with an IC50 value of 5.7 nM.
In vitro activity: In this study, inhibiting TRPV1 activity with SB-366791 significantly reduced Coxsackievirus B3 (CVB3) infection in induced-pluripotent stem cell-derived brain-like endothelial cells. SB-366791 could potentially limit viral entry into the brain, showcasing its potential as a treatment for neurotropic viruses. Reference: Front Cell Infect Microbiol. 2023 Apr 17;13:1171275. https://pubmed.ncbi.nlm.nih.gov/37139492/
In vivo activity: SB-366791 showed increased pain relief in both morphine-tolerant and non-tolerant mice without inducing genotoxic or mutagenic effects. SB-366791 led to an analgesic effect in the tail flick test. Behavioral results of the thermal nociception tests showed that SB-366791 had antinociceptive potential in both morphine-tolerant and non-tolerant mice without genotoxic or mutagenic effects. Reference: Naunyn Schmiedebergs Arch Pharmacol. 2020 Mar;393(3):481-490. https://pubmed.ncbi.nlm.nih.gov/31655852/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 28.8 100.00
Ethanol 2.9 10.00

Preparing Stock Solutions

The following data is based on the product molecular weight 287.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Mamana J, Humber GM, Espinal ER, Seo S, Vollmuth N, Sin J, Kim BJ. Coxsackievirus B3 infects and disrupts human induced-pluripotent stem cell derived brain-like endothelial cells. Front Cell Infect Microbiol. 2023 Apr 17;13:1171275. doi: 10.3389/fcimb.2023.1171275. PMID: 37139492; PMCID: PMC10149843. 2. Rita Pereira EM, Souza JM, Carobin NV, Silva JF, Santos DC, Silva Júnior CA, Binda NS, Borges MH, Pinto Nagem RA, Kushmerick C, Ferreira J, Castro Junior CJ, Ribeiro FM, Gomez MV. Phoneutria toxin PnTx3-5 inhibits TRPV1 channel with antinociceptive action in an orofacial pain model. Neuropharmacology. 2020 Jan 1;162:107826. doi: 10.1016/j.neuropharm.2019.107826. Epub 2019 Oct 22. PMID: 31647972. 3. Mazeto TK, Picada JN, Correa ÁP, Rebelo IN, Ribeiro MT, Gomez MV, de Souza AH. Antinociceptive and genotoxic assessments of the antagonist TRPV1 receptor SB-366791 on morphine-induced tolerance in mice. Naunyn Schmiedebergs Arch Pharmacol. 2020 Mar;393(3):481-490. doi: 10.1007/s00210-019-01748-6. Epub 2019 Oct 26. PMID: 31655852. 4. Lappin SC, Randall AD, Gunthorpe MJ, Morisset V. TRPV1 antagonist, SB-366791, inhibits glutamatergic synaptic transmission in rat spinal dorsal horn following peripheral inflammation. Eur J Pharmacol. 2006 Jul 1;540(1-3):73-81. doi: 10.1016/j.ejphar.2006.04.046. Epub 2006 May 6. PMID: 16737693.
In vitro protocol: 1. Mamana J, Humber GM, Espinal ER, Seo S, Vollmuth N, Sin J, Kim BJ. Coxsackievirus B3 infects and disrupts human induced-pluripotent stem cell derived brain-like endothelial cells. Front Cell Infect Microbiol. 2023 Apr 17;13:1171275. doi: 10.3389/fcimb.2023.1171275. PMID: 37139492; PMCID: PMC10149843. 2. Rita Pereira EM, Souza JM, Carobin NV, Silva JF, Santos DC, Silva Júnior CA, Binda NS, Borges MH, Pinto Nagem RA, Kushmerick C, Ferreira J, Castro Junior CJ, Ribeiro FM, Gomez MV. Phoneutria toxin PnTx3-5 inhibits TRPV1 channel with antinociceptive action in an orofacial pain model. Neuropharmacology. 2020 Jan 1;162:107826. doi: 10.1016/j.neuropharm.2019.107826. Epub 2019 Oct 22. PMID: 31647972.
In vivo protocol: 1. Mazeto TK, Picada JN, Correa ÁP, Rebelo IN, Ribeiro MT, Gomez MV, de Souza AH. Antinociceptive and genotoxic assessments of the antagonist TRPV1 receptor SB-366791 on morphine-induced tolerance in mice. Naunyn Schmiedebergs Arch Pharmacol. 2020 Mar;393(3):481-490. doi: 10.1007/s00210-019-01748-6. Epub 2019 Oct 26. PMID: 31655852. 2. Lappin SC, Randall AD, Gunthorpe MJ, Morisset V. TRPV1 antagonist, SB-366791, inhibits glutamatergic synaptic transmission in rat spinal dorsal horn following peripheral inflammation. Eur J Pharmacol. 2006 Jul 1;540(1-3):73-81. doi: 10.1016/j.ejphar.2006.04.046. Epub 2006 May 6. PMID: 16737693.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lappin SC, Randall AD, Gunthorpe MJ, Morisset V. TRPV1 antagonist, SB-366791, inhibits glutamatergic synaptic transmission in rat spinal dorsal horn following peripheral inflammation. Eur J Pharmacol. 2006 Jul 1;540(1-3):73-81. Epub 2006 May 6. PubMed PMID: 16737693.

2: Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM, Luis Hannan S, Lappin SC, Egerton J, Smith GD, Worby A, Howett L, Owen D, Nasir S, Davies CH, Thompson M, Wyman PA, Randall AD, Davis JB. Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology. 2004 Jan;46(1):133-49. Erratum in: Neuropharmacology. 2004 May;46(6):905. PubMed PMID: 14654105.

3: van Veghel D, Cleynhens J, Pearce LV, Blumberg PM, Van Laere K, Verbruggen A, Bormans G. Synthesis and biological evaluation of [¹¹C]SB366791: a new PET-radioligand for in vivo imaging of the TRPV1 receptor. Nucl Med Biol. 2013 Jan;40(1):141-7. doi: 10.1016/j.nucmedbio.2012.08.011. Epub 2012 Nov 7. PubMed PMID: 23141549.

4: Niiyama Y, Kawamata T, Yamamoto J, Furuse S, Namiki A. SB366791, a TRPV1antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Br J Anaesth. 2009 Feb;102(2):251-8. doi: 10.1093/bja/aen347. Epub 2008 Nov 26. PubMed PMID: 19038965.

5: Varga A, Németh J, Szabó A, McDougall JJ, Zhang C, Elekes K, Pintér E, Szolcsányi J, Helyes Z. Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat. Neurosci Lett. 2005 Sep 9;385(2):137-42. PubMed PMID: 15950380.